Hazard identification by methods of animal-based toxicology

Food and Chemical Toxicology

Volumn 40, Issue 2-3, 2002, Pages 145-191

  Barlow, S M ^a   Greig, J B ^b   Bridges, J W ^c   Carere, A ^d   Carpy, A J M ^e   Galli, C L ^f   Kleiner, J ^g   Knudsen, I ^h   Koeter H B W M ⁱ   Levy, L S ^a   Madsen, C ⁱ   Mayer, S ^j   Narbonne, J F ^e   Pfannkuch, F ^k   Prodanchuk, M G ^l   Smith, M R ^m   Steinberg, P ⁿ  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Sterling House Campus ^*

^c UNIVERSITY OF SURREY   (United Kingdom)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f UNIVERSITY OF MILAN   (Italy)

^g International Life Sciences Institute of Europe   (Belgium)

^h DANISH VETERINARY AND FOOD ADMINISTRATION   (Denmark)

ⁱ OECD   (France)

^j Red Bull GmbH   (France)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

^l Ministry of Health of Ukraine   (Ukraine)

^m UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

ⁿ UNIVERSITY OF POTSDAM   (Germany)

more..

Author keywords

Animal based methods; Food chemicals; Hazard identification; Repeated dose; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; CHEMICAL MUTAGEN; FOOD ADDITIVE; FOOD ALLERGEN; TERATOGENIC AGENT; TRACE ELEMENT; VOLATILE AGENT; XENOBIOTIC AGENT;

ANALYTIC METHOD; ARTICLE; ATHEROSCLEROSIS; CARCINOGENICITY; DIABETES MELLITUS; DIET; DIET SUPPLEMENTATION; EUROPE; FOOD ALLERGY; FOOD PROCESSING; FOOD SAFETY; GENETIC POLYMORPHISM; GENOTOXICITY; HAZARD ASSESSMENT; HEALTH STATUS; HUMAN; IMMUNOTOXICITY; LD 50; MAXIMUM TOLERATED DOSE; MUTAGENICITY; NEUROTOXICITY; NON INVASIVE MEASUREMENT; NONHUMAN; NUTRITIONAL HEALTH; NUTRITIONAL INTOLERANCE; OBESITY; PHYSICAL CHEMISTRY; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; TOXICITY TESTING; TOXICOKINETICS; TRANSGENIC ANIMAL;

ANIMALIA;

EID: 0036118572     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(01)00117-X     Document Type: Review

References (171)

1. Diagnosis of hypolactasia and lactose malabsorption
2. Low trehalase activity is associated with abdominal symptoms caused by edible mushrooms
3. Alternatives to the 2-species bioassay for the identification of potential human carcinogens
4. Uterotrophic activity of a "phytoestrogen-free" rat diet
5. Assessment of allergenic potential of novel proteins in food crops using the brown Norway rat model
6. Fetal origins of coronary heart disease
7. Workplace exposures and reproductive effects
8. Consideration of short-term carcinogenicity tests using transgenic mouse models
9. The value of animal teratogenicity testing for predicting human risk
10. Lactose malabsorption: Optimization of investigative methods
11. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[α]anthracene-induced lymphomas
12. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2
13. Evidence for decreasing quality of semen during past 50 years
14. Estrogen modulation: Tiered testing for human hazard evaluation
15. Developmental effects of dietary phytoestrogens in Sprague-Dawley rats and interactions of genistein and daidzein with rat estrogen receptors a and b in vitro
16. A tiered approach to threshold of regulation
17. An in vivo teratology screen utilizing pregnant mice
18. Association between adverse maternal and embryo-fetal effects in norfloxacin-treated and food deprived rabbits
19. Cancer risk assessment at the crossroads: The need to turn to a biological approach
20. Possible role of breath methane measurement in detecting carbohydrate malabsorption
21. A new method for determining allowable daily intakes
22. Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens
23. Characterisation of antibody responses induced in mice by food proteins: Influence of route of exposure
24. A general QSAR model for predicting the acute toxicity of pesticides to Lepomis macrochirus
25. Screening methods for thyroid hormone disruptors
26. Forum: Meeting overview: Mechanisms of susceptibility to mouse liver carcinogenesis
27. Hazard characterisation of chemicals in food and diet: Dose-response, mechanisms, and extrapolation issues
28. Mathematical modelling and quantitative methods
29. Methods of in vitro toxicology
30. A simple, sensitive, and objective method for early assessment of acrylamide neuropathy in rats
31. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor
32. Food and Drug Administration proposed testing guidelines for reproduction studies
33. Additional recommended studies - Part C: Neurotoxicity studies
34. Testing of environmental agents for developmental and reproductive toxicity
35. FDA perspectives on the use of teratology data for human risk assessment
36. Endocrine Screening Methods Workshop report: Detection of estrogenic and androgenic hormonal and antihormonal activity for chemicals that act via receptor or steroidogenic enzyme mechanisms
37. Sucralose - An overview of the toxicity data
38. Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment
39. Dietary restriction and cancer
40. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases
41. Prenatal immunotoxicant exposure and postnatal autoimmune disease
42. Developmental immunotoxicology
43. International collaborative immunotoxicity study. Report of validation study of assessment of direct immunotoxicity in the rat
44. The duration of toxicity studies required to support repeated dosing in clinical investigations - A toxicologist's opinion
45. Proceedings of workshop on the evaluation of alternative methods for carcinogenicity testing, 1-3 November, 2000
46. IPCS harmonisation of approaches to the assessment and risk from exposure to chemicals
47. The restriction site mutation assay: A review of the methodology, development and the current status of the technique
48. Induction of the CYP1A1 dioxin-responsive enhancer in transgenic mice
49. Histocompatibility and isoenzyme differences in commercially supplied "BALB/c" mice
50. Effect of acrylamide on rotarod performance and sciatic nerve beta-glucuronidase of rats
51. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: A report of the U. S. EPA-sponsored workshop
52. Use of transgenic animals in toxicology
53. Oral sensitization to food proteins: A Brown Norway rat model
54. Evidence for carbon tetrachloride- and ethanol-induced lipid peroxidation in vivo demonstrated by ethane production in mice and rats
55. Threshold of toxicological concern for chemical substances present in the diet: A practical tool for assessing the need for toxicity testing
56. Reproductive toxicity testing: Evaluation and developing new test systems
57. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
58. Role of CYP2E1 in the hepatotoxicity of acetaminophen
59. A murine model of IgE-mediated cow's milk hypersensitivity
60. A murine model peanut anaphylaxis: T- and B-cell responses to a major peanut allergens mimic human responses
61. -/- null mutant mice develop normally but show deficient drug metabolism
62. An investigation of genetic variation within a series of congenic strains of mice
63. DNA damage and repair in mammalian cells in vitro and in vivo as indicators of exposure to carcinogens
64. The use of genetically altered animals in toxicology
65. An overview and comparison of reproductive and developmental toxicity regulations
66. Testing of pharmaceutical agents for reproductive toxicity
67. The use of genetically modified animals in carcinogenicity bioassays
68. Dietary deprivation induces fetal loss and abortion in rabbits
69. Development of methods to predict the allergenic potential of genetically modified foods and novel protein products
70. Assessment of the allergenic potential of foods derived from genetically engineered crop plants
71. Allergy to bovine β-lactoglobulin: Specificity of immunoglobulin E generated in the Brown Norway rat to tryptic and synthetic peptides
72. The rabbit in atherosclerosis research
73. Transgenic laboratory animal models in atherosclerosis research
74. Extravascular lipid disposition and morphology of atherosclerosis in heterozygous WHHL rabbits fed vegetable (n-6) and marine (n-3) oils
75. Correlation of a structural class with no-observed-effect levels: A proposal for establishing a threshold of concern
76. Application of a threshold of toxicological concern in the safety evaluation of certain flavouring substances
77. Changes in the classification of carcinogenic chemicals in the work area (Ch III of the German List of MAK and BAT values)
78. Concordance of the toxicity of pharmaceuticals in humans and animals
79. Current and Expected Assessment Approaches: Revision of the Conceptual Framework
80. What is the ideal approach to reproductive toxicity testing?
81. Food restriction during organogenesis in rabbits: Effects on reproduction and the offspring
82. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2
83. Toxic responses of the liver
84. Different poisoning sensitivity of adults and children (0-15 years) and requirements for animal-based toxicology experiments
85. Ethical review of regulatory toxicity guidelines involving experiments on animals: The example of endocrine disrupters
86. Serum levels of TCDD and dioxin-like chemicals in rhesus monkeys chronically exposed to dioxin: Correlation of increased serum PCB levels with endometriosis
87. Absence of lipid peroxidation as determined by ethane exhalation in rats treated with TCDD
88. Gene knockout and transgenic technologies in risk assessment: The next generation
89. Impact of knockout mice in toxicology
90. Effects of carbaryl and naphthalene on rat hepatic CYP1A1/2: Potential binding to Ah receptor and 4S benzo(a)pyrene-binding protein
91. Species sensitivity and prediction of teratogenic potential
92. Potential human developmental toxicants and the role of animal testing in their identification and characterisation
93. Use of transgenic mutational test systems in risk assessment of carcinogens
94. Characterization of a murine Ahr null allele: Involvement of the Ah receptor in hepatic growth and development
95. Use of immunotoxicity data in health risk assessments: Uncertainties and research to improve the process
96. Regulation of spermatogenesis
97. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract?
98. Heterologous expression of drug-metabolizing-enzymes in cellular and whole animal-models
99. Food Safety in Europe (FOSIE): Risk assessment of chemicals in food and diet: Overall introduction
100. An updated review of environmental estrogen and androgen mimics and antagonists
101. The E-screen assay as a tool to identify estrogens: An update on estrogenic environmental chemicals
102. Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals-scientific perspective
103. The phytoestrogen content of rodent diets
104. Toxicology of the adrenal, thyroid and endocrine pancreas
105. Toxic responses of the reproductive system
106. Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies
107. History and objectives of quantitative drug design
108. A transgenic mouse expressing human CYP1A2 in the pancreas
109. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression
110. The parameterization of lipophilicity and other structural properties in drug design
111. The contribution of epidemiology
112. IgE and mast cell responses on intestinal allergen exposure: A murine model to study the onset of food allergy
113. Host resistance models
114. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe
115. Deteriorating trends in male reproduction: Idiopathic or environmental?
116. Carcinoma in situ and seminoma in equine testis
117. Interstitial cell tumour and germ cell tumour with carcinoma in situ in rabbit testes
118. Transgenic assays for mutations and cancer: Current status and future perspectives
119. Use of transgenic animals in understanding molecular mechanisms of toxicity
120. Humanized xenobiotic response in mice expressing nuclear receptor SXR
121. Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters
122. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice
123. The IgG response of Brown Norway rats to oral administration of ovalbumin